Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Quarterly Risperidone (QUAR) in Schizophrenia
NCT06276361Phase 1Completed
- Sponsor
- Laboratorios Farmacéuticos ROVI
- Start
- Sep 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of risperidone in schizophrenia (4 arms), sponsored by Laboratorios Farmacéuticos ROVI. Primary endpoints: Terminal elimination rate constant (lambda_z) at Day 196, Terminal elimination half-life at Day 196 and 9 more. Started Sep 2023; status: completed.
02
Drugs
risperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06276361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06276361.